Avalyn Raises $175m To Fund Inhaled Versions Of Pulmonary Fibrosis Drugs

 
• By Joseph Haas
  
Pulmonary disease
Avalyn hopes its inhaled therapies will improve on the profiles of existing IPF drugs • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business